drugset
drugset / Trial / NCT07368608

A Study of BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol（LDL-C）

NCT07368608 ↗

Phase 1/2 Not yet recruiting 340 enrolled BeBetter Med Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

This Phase I/II clinical trial is designed to evaluate, through a single-dose Phase I segment and a multiple-dose Phase II segment, the safety/tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) characteristics of BEBT-701 administered by subcutaneous injection in patients with mild to moderate hypertension and elevated LDL-C , and to explore its preliminary efficacy.

Timeline

Start
2026-01-26
Primary completion
2028-11-30
Completion
2029-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject BEBT-701 Unknown 100 mg Subcutaneous
Subject BEBT-701 Unknown 200 mg Subcutaneous
Subject BEBT-701 Unknown 400 mg Subcutaneous
Subject BEBT-701 Unknown 800 mg Subcutaneous
Subject BEBT-701 Unknown 1200 mg Subcutaneous

Indications

low density lipoprotein cholesterol, mild elevation of